Payment overview · 2025
General Payments
$291.09
15 reported records · 11 companies
Healthcare provider profile · identity verified
Travis M Daise, MD
Allopathic & Osteopathic Physicians|Family Medicine · GOODLAND, KS · NPI 1184621997
Verified facts
What the public records show
CMS Open Payments records show Travis M Daise, MD received $291.09 in general payments during 2025 across 15 reported records.
Amgen Inc. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 368 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.83 | 17.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $39.60 | 13.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.81 | 13.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $26.88 | 9.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.91 | 7.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.53 | 7.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.28 | 6.6% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $19.17 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.12 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.52 | 5.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $16.44 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.09 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $26.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
368 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 638 | 130 |
| Potassium Chloride | Potassium Chloride | 506 | 92 |
| Furosemide | Furosemide | 453 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 377 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 377 | 70 |
| Losartan Potassium | Losartan Potassium | 376 | 86 |
| Eliquis | Apixaban | 368 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 361 | 66 |
| Lisinopril | Lisinopril | 306 | 74 |
| Gabapentin | Gabapentin | 250 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 232 | 50 |
| Omeprazole | Omeprazole | 224 | 55 |
| Metformin Hcl | Metformin Hcl | 200 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 60 |
| Buspirone Hcl | Buspirone Hcl | 175 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 152 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 37 |
| Tramadol Hcl | Tramadol Hcl | 149 | 31 |
| Pregabalin | Pregabalin | 145 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 37 |
| Montelukast Sodium | Montelukast Sodium | 142 | 35 |
| Sertraline Hcl | Sertraline Hcl | 136 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 131 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 125 | 25 |
| Simvastatin | Simvastatin | 123 | 25 |
| Warfarin Sodium | Warfarin Sodium | 121 | 14 |
| Meloxicam | Meloxicam | 119 | 28 |
| Spironolactone | Spironolactone | 117 | 21 |
| Jardiance | Empagliflozin | 114 | 22 |
| Allopurinol | Allopurinol | 112 | 25 |
| Celecoxib | Celecoxib | 108 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 101 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 20 |
| Farxiga | Dapagliflozin Propanediol | 97 | 18 |
| Bumetanide | Bumetanide | 95 | 17 |
| Mirtazapine | Mirtazapine | 94 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 34 |
| Trazodone Hcl | Trazodone Hcl | 88 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 25 |
| Ondansetron Odt | Ondansetron | 82 | 22 |
| Xarelto | Rivaroxaban | 80 | 11 |
| Carvedilol | Carvedilol | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 78 | 13 |
| Famotidine | Famotidine | 77 | 17 |
| Donepezil Hcl | Donepezil Hcl | 73 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 71 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 70 | 15 |
| Ozempic | Semaglutide | 70 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 18 |
| Synthroid | Levothyroxine Sodium | 69 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 67 | 11 |
| Fentanyl | Fentanyl | 63 | suppressed |
| Mounjaro | Tirzepatide | 63 | 13 |
| Gemtesa | Vibegron | 62 | 14 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Ezetimibe | Ezetimibe | 61 | 17 |
| Cephalexin | Cephalexin | 60 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Prednisone | Prednisone | 60 | 32 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Atenolol | Atenolol | 58 | 11 |
| Finasteride | Finasteride | 56 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 55 | 12 |
| Sucralfate | Sucralfate | 52 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Baclofen | Baclofen | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 13 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Nystatin | Nystatin | 40 | 17 |
| Linzess | Linaclotide | 39 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 28 |
| Glipizide | Glipizide | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Azithromycin | Azithromycin | 32 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Azelastine Hcl | Azelastine Hcl | 29 | 13 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Austedo | Deutetrabenazine | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Valsartan | Valsartan | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Mupirocin | Mupirocin | 15 | 11 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Trulicity | Dulaglutide | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.09 · 15 records | Amgen Inc. | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, EVENITY, EXOGEN ULTRASOUND BONE HEALING SYSTEM, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, REPATHA, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error